Neurology® Podcast
Highlights of the 2024 European Stroke Organization Conference
Jul 1, 2024
Dr. Seemant Chaturvedi discusses recent trials from the European Stroke Organization Conference, including studies on thrombolysis, blood pressure management, and using colchicine for non-cardiogenic strokes. The podcast highlights the importance of recognizing stroke symptoms, exploring new treatment advancements, and the cultural aspects of attending international conferences.
22:35
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Tenecteplase did not improve outcomes for minor ischemic stroke with intracranial occlusion.
- Tenecteplase showed benefits in ischemic stroke patients without thrombectomy access within extended window.
Deep dives
TEMPO2 Trial: Tenecteplase Study for Acute Stroke Care
The TEMPO2 trial focused on comparing tenecteplase with standard care for minor ischemic stroke patients with evidence of intracranial occlusion. Over 800 patients were enrolled within 12 hours of symptom onset. Disappointingly, the tenecteplase group did not show better outcomes at 90 days compared to the control group, and there were more deaths and symptomatic hemorrhages in the tenecteplase group. The study suggests that for patients with minor strokes and intracranial occlusion, single or dual antiplatelet therapy remains the preferred treatment.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
